Stock Markets March 6, 2026

STOXX 600 edges up as Middle East conflict drags European stocks toward weekly loss

Benchmark posts a small gain on Friday but is set for its worst week in nearly a year as defense gains are offset by healthcare declines

By Jordan Park
STOXX 600 edges up as Middle East conflict drags European stocks toward weekly loss

Europe's STOXX 600 rose modestly on Friday, but the index is on track for its steepest weekly drop in almost a year as renewed escalation in the Middle East undermines investor risk appetite. Defense companies provided the main uplift, while weakness in healthcare - including significant declines for Roche and Zealand Pharma after mid-stage obesity drug data - capped broader gains. Markets are also awaiting euro zone GDP and employment revisions and speeches from European Central Bank officials.

Key Points

  • STOXX 600 rose 0.2% to 606.26 by 0805 GMT but stayed near one-month lows.
  • Defense stocks provided the largest sectoral boost, while healthcare declines capped gains.
  • Roche fell 1.7% and Zealand Pharma dropped 31.2% after reporting mid-stage data on an experimental obesity drug.

Europe's STOXX 600 eked out a small gain on Friday, but remained close to one-month lows and was headed for its worst weekly performance in nearly a year as turmoil in the Middle East dented global risk appetite and unsettled financial markets.

By 0805 GMT the pan-European index had climbed 0.2% to 606.26 points, yet the modest advance did little to erase heavy declines seen earlier in the week. The widening conflict in the Middle East over the past seven days showed no obvious signs of abating, a dynamic market participants said has weighed on sentiment and helped drive European equities toward a roughly 4.6% drop for the week.

Within the STOXX 600, defense stocks were the clearest source of upward pressure on the index, delivering the largest sectoral lift. Offsetting those gains, however, were losses in the healthcare sector. Shares of Roche fell 1.7% and Zealand Pharma tumbled 31.2% after both pharmaceutical companies disclosed mid-stage study data for an experimental obesity treatment. Those moves in individual healthcare names limited the broader market advance.

Investors were also focused on a clutch of scheduled data releases and central bank commentary later in the day. A revised reading of euro zone fourth-quarter gross domestic product and employment figures was due, and market participants expected remarks from European Central Bank President Christine Lagarde and ECB board member Isabel Schnabel that could influence market direction.

On the corporate front, Lufthansa gained 2.8% after reporting results for its 2025 financial year that beat expectations. The airline's stronger-than-expected performance provided an isolated source of strength within travel and transport-related segments of the market.

Separately, some market research and stock idea services were referenced in market chatter, noting the routine evaluation of securities such as Lufthansa using automated tools that screen companies across many financial metrics and historic performance indicators, and reporting whether specific stocks are included in their strategies.

Overall, however, ongoing geopolitical tension in the Middle East and the prospect of key euro zone economic data and ECB commentary left markets in a cautious posture as the week drew to a close.

Risks

  • Escalation of the Middle East conflict - impacts broad equity markets and investor risk appetite, particularly in Europe.
  • Upcoming revised euro zone Q4 GDP and employment readings - could alter market expectations for growth-sensitive sectors.
  • ECB speeches from President Christine Lagarde and board member Isabel Schnabel - may affect market volatility and monetary policy expectations.

More from Stock Markets

Prenetics Board Authorizes $40M Buyback as Shares Rise 16% Mar 6, 2026 Maris-Tech Shares Drop After Registered Direct Offering Is Announced Mar 6, 2026 Tel Aviv Stocks Tick Higher as TA-35 Reaches New Peak Mar 6, 2026 Morgan Stanley Names Top IT Hardware Stocks Focused on Data Center and AI Demand Mar 6, 2026 Servier to Buy Day One Biopharmaceuticals in $2.5 Billion Cash Deal; DAWN Stock Rockets Mar 6, 2026